男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Asia-Pacific

Japan approves rollout of protein-based Novavax COVID-19 vaccine

Xinhua | Updated: 2022-04-19 14:07
Share
Share - WeChat
A vial and sryinge are seen in front of a displayed Novavax logo in this illustration taken Jan 11, 2021. [Photo/Agencies]

TOKYO - Japan's health ministry on Tuesday approved the use of a COVID-19 vaccine developed by US pharmaceutical company Novavax to be used on people aged 18 and older.

The Novavax vaccine will mark the fourth COVID-19 inoculation approved in Japan, although will be the first protein-based vaccine compared to those developed by Pfizer and Moderna that are messenger RNA-based (mRNA) jabs.

The ministry hopes the Novavax jab can be administered to those who are likely to show allergic reactions to mRNA vaccines so they can still be vaccinated against the virus which has yet to be brought under control in Japan.

According to Japan's public broadcaster NHK, protein-based vaccines are known to cause relatively fewer reactions, with the thinking being among the ministry that this will help the uptake of those who are as yet unvaccinated because they have been worried about side effects.

The Novavax vaccine requires recipients to be jabbed twice with a three-week period between doses, the ministry said, although a third booster shot will be allowed six months or more after the second jab.

Takeda Pharmaceutical will manufacture the jab locally and distribute the Novavax vaccine and is under contract to supply 150 million doses of the vaccine to the government within a year, according to official accounts.

The rollout, they said, is expected to begin in late May, with Health Minister Shigeyuki Goto saying on Tuesday that the government purchased the vaccine last September to make sure Japan was in possession of a stable supply should restrictions be applied on overseas vaccines.

Goto also said Novavax as a vaccine also got the green light from the government specifically because it is protein-based and is regarded as safe and effective.

He added that the Japanese government had always intended to procure a variety of different vaccines so as to offer the public more choices.

Local governments have been asked by the health ministry to open at least one site where the Novavax vaccine can be administered to make sure that those who prefer the protein-based jab, or require a non-mRNA for whatever reason, have access to it.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 荆州市| 太保市| 巢湖市| 安远县| 云林县| 宁海县| 满洲里市| 镇赉县| 巴马| 尼木县| 南华县| 揭阳市| 诏安县| 霍州市| 舟曲县| 咸宁市| 绥滨县| 太保市| 海盐县| 从化市| 交城县| 扶绥县| 会同县| 固安县| 栾川县| 临漳县| 云霄县| 肥城市| 滨州市| 任丘市| 雅安市| 右玉县| 安溪县| 阳原县| 织金县| 怀来县| 彭阳县| 赞皇县| 介休市| 时尚| 桃源县|